Need Help?
Contact Us

IT TAKES COLLABORATION TO MAKE SCIENCE MORE MEANINGFUL

  • News Releases

    Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017

    MARLBOROUGH, Mass., Jan. 9, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion during the fourth quarter ended December 31, 2017. This represents growth of approximately 9.9 percent on a reported basis, approximately 8.1 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates) and approximately 6.8 percent on an organic basis, all compared to the prior year period. Organic revenue growth excludes the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings, Inc. (EndoChoice) and Symetis SA (Symetis), with no prior year comparable sales.

    Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation)

    For the year ended December 31, 2017, the Company generated sales, based upon preliminary unaudited financial information, of approximately $9.05 billion. This represents growth of approximately 7.9 percent on a reported basis, approximately 7.8 percent on an operational basis and approximately 6.6 percent on an organic basis, all compared to the prior year period.

    Preliminary net sales for the fourth quarter:











    Three Months Ended


    Change

    (in billions / unaudited)

    December 31,


    As Reported
    Basis


    Less: Impact
    of Foreign
    Currency


    Operational
    Basis

    2017

    2016


















       Interventional Cardiology

    $

    0.64


    $

    0.58



    8.8


    %


    1.9


    %


    6.9


    %


       Peripheral Interventions

    0.28


    0.26



    8.4


    %


    1.7


    %


    6.7


    %


    Cardiovascular

    0.91


    0.84



    8.7


    %


    1.9


    %


    6.8


    %


       Cardiac Rhythm Management

    0.49


    0.47



    3.4


    %


    2.2


    %


    1.2


    %


       Electrophysiology

    0.08


    0.06



    20.7


    %


    3.0


    %


    17.7


    %


    Rhythm Management

    0.56


    0.54



    5.4


    %


    2.2


    %


    3.2


    %


       Endoscopy

    0.44


    0.38



    14.8


    %


    1.7


    %


    13.1


    %


       Urology and Pelvic Health

    0.31


    0.27



    12.7


    %


    1.4


    %


    11.3


    %


       Neuromodulation

    0.19


    0.16



    15.5


    %


    0.9


    %


    14.6


    %


    MedSurg

    0.93


    0.82



    14.2


    %


    1.4


    %


    12.8


    %














    Net Sales

    $

    2.41


    $

    2.19



    9.9


    %


    1.8


    %


    8.1


    %


    Preliminary net sales as shown are rounded, while growth rates are based on preliminary, non-rounded amounts and may not recalculate precisely. Certain columns and rows within the table above may not add due to the use of rounded numbers.


    Sales growth rates that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales are not prepared in accordance with U.S. GAAP.

     

    Preliminary net sales for the full year:










    Twelve Months Ended


    Change

    (in billions / unaudited)

    December 31,


    As Reported
    Basis


    Less: Impact
    of Foreign
    Currency


    Operational
    Basis

    2017

    2016


















       Interventional Cardiology

    $

    2.42


    $

    2.28



    6.2


    %


    0.1


    %


    6.1


    %


       Peripheral Interventions

    1.08


    1.01



    6.5


    %


    (0.1)


    %


    6.6


    %


    Cardiovascular

    3.50


    3.29



    6.3


    %


    0.0


    %


    6.3


    %


       Cardiac Rhythm Management

    1.90


    1.85



    2.5


    %


    0.2


    %


    2.3


    %


       Electrophysiology

    0.28


    0.24



    14.5


    %


    0.1


    %


    14.4


    %


    Rhythm Management

    2.17


    2.09



    3.9


    %


    0.2


    %


    3.7


    %


       Endoscopy

    1.62


    1.44



    12.4


    %


    0.1


    %


    12.3


    %


       Urology and Pelvic Health

    1.12


    1.01



    11.8


    %


    0.2


    %


    11.6


    %


       Neuromodulation

    0.64


    0.56



    14.2


    %


    0.1


    %


    14.1


    %


    MedSurg

    3.38


    3.00



    12.5


    %


    0.1


    %


    12.4


    %














    Net Sales

    $

    9.05


    $

    8.39



    7.9


    %


    0.1


    %


    7.8


    %


    Preliminary net sales as shown are rounded, while growth rates are based on preliminary, non-rounded amounts and may not recalculate precisely. Certain columns and rows within the table above may not add due to the use of rounded numbers.


    Sales growth rates that exclude the impact of changes in foreign currency exchange rates and/or the impact of recent acquisitions with significant sales are not prepared in accordance with U.S. GAAP.

     

    All of the information in this press release is preliminary and subject to completion of year end financial reporting processes, reviews and audit.

    J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
    As previously announced, Boston Scientific will participate in the J.P. Morgan Healthcare Conference today in San Francisco, CA. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:00 a.m. PT. At 8:30 a.m. PT, Mike will be joined by Dan Brennan, executive vice president and chief financial officer, Professor Ian Meredith, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host analyst and audience members.

    A live webcast of the presentation and question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. A replay of the webcast will be accessible at investors.bostonscientific.com beginning approximately one hour following the completion of the event.

    Conference Call on Thursday, February 1, 2018
    As previously announced, Boston Scientific will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2017 and provide first quarter and full year 2018 guidance on Thursday, February 1, 2018 at 8:00 a.m. EST. A live webcast of the conference call will be available on the Investor Relations section of the website at investors.bostonscientific.com. A replay of the webcast will be archived and available at investors.bostonscientific.com beginning approximately one hour following the completion of the meeting.

    About Boston Scientific
    Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

    Cautionary Statement Regarding Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.

    These forward-looking statements include, among other things, statements regarding our expected net sales, GAAP, operational and organic revenue growth rates, our financial performance, our business plans and our positioning for revenue and earnings growth.

    Our expectations about quarterly and full year results are based on preliminary unaudited information about the fourth quarter of 2017 and are subject to revision. Although the quarter is now completed, we are still in the early stages of our standard financial reporting closing procedures. Accordingly, as we complete our normal quarter-end and year-end closing and review processes, actual results could differ materially from these preliminary estimates. Factors that could cause our actual results for the fourth quarter of 2017 to differ materially from those contemplated by these forward-looking statements include, but are not limited to, inaccurate assumptions; unrecorded expenses; changes in estimates or judgments; and facts or circumstances affecting the application of the Company's critical accounting policies, including revenue recognition.

    If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

    Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions, new product introductions and the market acceptance of those products, markets for our products, expected pricing environment, expected procedural volumes, the closing and integration of acquisitions, clinical trial results, demographic trends, intellectual property rights, litigation, financial market conditions, the execution and effect of our restructuring program, the execution and effect of our business strategy, including our cost-savings and growth initiatives and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

    Use of Non-GAAP Financial Information
    A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this news release.

     

    CONTACTS:


    Media:

    Kate Haranis


    508-683-6585 (office)


    Media Relations


    Boston Scientific Corporation


    kate.haranis@bsci.com



    Investors:

    Susie Lisa, CFA


    508-683-5565 (office)


    Investor Relations


    Boston Scientific Corporation


    investor_relations@bsci.com

     

     

    BOSTON SCIENTIFIC CORPORATION

    TOTAL COMPANY NET SALES GROWTH



    Q4 2017 Preliminary / Unaudited Net Sales as compared to Q4 2016



    Total BSC

    Percentage change in net sales, as reported

    9.9

    %

    Less: Impact of foreign currency fluctuations

    1.8

    %

    Percentage change in net sales, operational

    8.1

    %

    Less: Impact of significant acquisitions

    1.3

    %

    Percentage change in net sales, organic

    6.8

    %



    FY2017 Preliminary / Unaudited Net Sales as compared to FY2016



    Total BSC

    Percentage change in net sales, as reported

    7.9

    %

    Less: Impact of foreign currency fluctuations

    0.1

    %

    Percentage change in net sales, operational

    7.8

    %

    Less: Impact of significant acquisitions

    1.2

    %

    Percentage change in net sales, organic

    6.6

    %

     

    Use of Non-GAAP Financial Measures

    To supplement our financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including operational net sales, which exclude the impact of changes in foreign currency exchange rates, and organic net sales, which exclude the impact of foreign currency exchange rates and the impact of recent acquisitions with significant sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States.

    To calculate operational net sales that exclude the impact of changes in foreign currency exchange rates, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. To calculate organic net sales, the impact of recent acquisitions with significant sales is removed from operational net sales.  The GAAP financial measure most directly comparable to operational net sales and organic net sales growth rate percentages is growth rate percentages using net sales on a GAAP basis. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

    Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. With the exception of the impact of recent acquisitions with significant sales, the adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments' measures of net sales and profit or loss. These adjustments are excluded from the segment measures that are reported to our chief operating decision maker that are used to make operating decisions and assess performance.

    We believe that presenting operational net sales and organic net sales, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision making and allows investors to see our results "through the eyes" of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

    SOURCE Boston Scientific Corporation